$0.62
(Market cap
$6,839 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-24.4 %
-
Industry P/E
--
-
EV/EBITDA
-14.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-6.9
-
Face value
--
-
Shares outstanding
144,397,682
7 Years Aggregate
CFO
$-713.03 Mln
EBITDA
$-835.07 Mln
Net Profit
$-930.03 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vaxcyte (PCVX)
| 3.8 | -11.3 | -16.7 | 35.2 | -1.8 | 16.8 | -- |
|
BSE Sensex
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Midcap 400
| 13.4 | 2.9 | 11.1 | 24.4 | 14.3 | 6.6 | 9.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Vaxcyte (PCVX)
| -43.6 | 30.1 | 31.0 | 101.6 | -10.5 |
|
S&P Midcap 400
| 5.9 | 12.1 | 14.4 | -14.5 | 23.2 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vaxcyte (PCVX)
|
47.9 | 6,838.7 | 0.0 | -946.5 | -- | -32.1 | -- | 2.3 |
| 283.0 | 40,461.0 | 4,286.9 | 577.2 | 9.8 | 88.2 | 76.3 | 37.6 | |
| 188.5 | 8,949.1 | 4,027.0 | -184.7 | 11.3 | -5.9 | -- | 2.9 | |
| 104.9 | 20,026.1 | 3,247.0 | -208.0 | -5.5 | -8.7 | -- | 8.3 | |
| 97.9 | 20,422.4 | 819.6 | -1,183.8 | -141.4 | -143.4 | -- | 29.0 | |
| 179.4 | 30,617.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.8 | 5.0 | |
| 50.7 | 18,823.5 | 2,225.0 | -3,194.0 | -143.4 | -38.2 | -- | 2.5 | |
| 614.6 | 66,620.0 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 15.5 | 2.1 | |
| 540.6 | 23,340.2 | 3,169.8 | 1,287.4 | 51.4 | 20.6 | 20.3 | 4.0 | |
| 444.1 | 113,407.9 | 12,255.1 | 4,338.3 | 31.7 | 23.7 | 26.5 | 5.9 |
Shareholding Pattern
View DetailsAbout Vaxcyte (PCVX)
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational... pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Read more
-
Co-Founder, CEO & Director
Mr. Grant E. Pickering M.B.A.
-
Co-Founder, CEO & Director
Mr. Grant E. Pickering M.B.A.
-
Headquarters
San Carlos, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Vaxcyte (PCVX)
What is the current share price of Vaxcyte Inc (PCVX) Today?
The share price of Vaxcyte Inc (PCVX) is $47.91 (NASDAQ) as of 12-Jun-2026 13:37 EDT. Vaxcyte Inc (PCVX) has given a return of -1.78% in the last 3 years.
What is the current PB & PE ratio of Vaxcyte Inc (PCVX)?
Since, TTM earnings of Vaxcyte Inc (PCVX) is negative, P/E ratio is not available.
The P/B ratio of Vaxcyte Inc (PCVX) is 2.35 times as on 05-Jun-2026, a 42 discount to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-8.19
|
2.34
|
|
2024
|
-21.53
|
3.02
|
|
2023
|
-15.14
|
4.91
|
|
2022
|
-13.95
|
3.27
|
|
2021
|
-12.36
|
4.36
|
What is the 52 Week High and Low of Vaxcyte Inc (PCVX)?
The 52-week high and low of Vaxcyte Inc (PCVX) are Rs 64.79 and Rs 29.08 as of 13-Jun-2026.
What is the market cap of Vaxcyte Inc (PCVX)?
Vaxcyte Inc (PCVX) has a market capitalisation of $ 6,839 Mln as on 05-Jun-2026. As per SEBI classification, it is a Mid Cap company.
Should I invest in Vaxcyte Inc (PCVX)?
Before investing in Vaxcyte Inc (PCVX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.